home / stock / tgtx / tgtx quote
Last: | $16.30 |
---|---|
Change Percent: | -0.59% |
Open: | $16.99 |
Close: | $16.30 |
High: | $17.15 |
Low: | $16.23 |
Volume: | 1,945,268 |
Last Trade Date Time: | 05/31/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$16.3 | $16.99 | $16.3 | $17.15 | $16.23 | 1,945,268 | 05-31-2024 |
$16.89 | $16.58 | $16.89 | $17 | $16.42 | 1,768,762 | 05-30-2024 |
$16.36 | $16.63 | $16.36 | $16.79 | $16.29 | 1,594,608 | 05-29-2024 |
$16.85 | $16.81 | $16.85 | $16.88 | $16.36 | 3,210,981 | 05-28-2024 |
$16.71 | $17.13 | $16.71 | $17.155 | $16.6 | 1,298,206 | 05-27-2024 |
$16.71 | $17.13 | $16.71 | $17.155 | $16.6 | 1,298,206 | 05-24-2024 |
$16.98 | $17.71 | $16.98 | $17.71 | $16.95 | 1,990,169 | 05-23-2024 |
$17.7 | $16.55 | $17.7 | $17.8738 | $16.54 | 3,080,604 | 05-22-2024 |
$16.6 | $16.38 | $16.6 | $16.74 | $16.35 | 1,448,847 | 05-21-2024 |
$16.48 | $16.62 | $16.48 | $16.649 | $16.225 | 3,016,028 | 05-20-2024 |
$16.48 | $17.46 | $16.48 | $17.52 | $16.335 | 3,268,639 | 05-17-2024 |
$17.42 | $17.72 | $17.42 | $17.735 | $17.29 | 2,024,771 | 05-16-2024 |
$17.72 | $18.29 | $17.72 | $18.41 | $17.63 | 3,337,741 | 05-15-2024 |
$17.96 | $17.51 | $17.96 | $18.37 | $17.51 | 3,735,650 | 05-14-2024 |
$17.32 | $16.75 | $17.32 | $17.57 | $16.63 | 4,316,617 | 05-13-2024 |
$16.62 | $16.91 | $16.62 | $17.125 | $16.6 | 2,226,828 | 05-10-2024 |
$16.92 | $17.23 | $16.92 | $17.34 | $16.83 | 2,679,217 | 05-09-2024 |
$17.12 | $16.99 | $17.12 | $17.63 | $16.98 | 4,228,467 | 05-08-2024 |
$17.18 | $16.5 | $17.18 | $17.2799 | $16.42 | 4,532,309 | 05-07-2024 |
$16.51 | $16.26 | $16.51 | $16.63 | $15.76 | 3,773,273 | 05-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI ® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the...
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple scl...
2024-05-14 12:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...